ASTRAZENECA PHARMA INDIA LTD. Q4 FY26 Results

Summary

AstraZeneca Pharma India Limited recorded strong financial performance for the full financial year ended March 31, 2026, with revenue from operations growing by 32.58% year-on-year to ₹2,275.58 crore. This robust top-line growth translated into a substantial 62.02% increase in profit after tax, which reached ₹187.52 crore for FY26. While the fourth quarter revenue also showed a healthy 20.42% year-on-year increase to ₹578.61 crore, the quarter's profit after tax saw a decline of 22.95% to ₹44.88 crore compared to the prior year period. The company's full-year EBITDA stood at ₹286.03 crore, representing an EBITDA margin of 12.57%. Additionally, the Board recommended a dividend of ₹36 per equity share for FY26, pending shareholder approval.

Key Highlights

1. 1

   AstraZeneca Pharma India Limited reported a significant 32.58% year-on-year increase in revenue from operations, reaching ₹2,275.58 crore for the financial year ended March 31, 2026.

2. 2

   Profit after tax for FY26 surged by 62.02% to ₹187.52 crore, compared to ₹115.74 crore in the previous fiscal year.

3. 3

   For the fourth quarter ended March 31, 2026, revenue from operations grew by 20.42% year-on-year to ₹578.61 crore.

4. 4

   However, profit after tax for Q4 FY26 declined by 22.95% year-on-year to ₹44.88 crore from ₹58.25 crore in Q4 FY25.

5. 5

   The company's EBITDA for FY26 stood at ₹286.03 crore, resulting in an EBITDA margin of 12.57%.

6. 6

   The Board has recommended a final dividend of ₹36 per equity share for the financial year 2025-26, subject to shareholder approval.